07/28/2026
By the time a peptide sales email reaches your clinic manager, some of your patients have already been ordering them online for months.
One endocrinologist saw roughly a dozen patients in a single month who brought peptides up on their own. Nobody prescribed them. They found them. That's the real front line, and it isn't the inbox. It's the exam room.
Which means the useful question was never whether a program should sell peptides. It's what your team says when a patient asks.
Our latest post walks through what July's FDA advisory vote actually did, what it didn't, and how to be ready for that conversation.
read the full blog at: https://www.sharedhealthservices.com/post/peptides-in-wound-care-what-fda-s-503a-review-means-and-what-s-landing-in-your-inbox
"Physician-use peptides. Third-party tested. A new revenue stream without a heavy lift." If an email like that has reached your wound care program — and this month, three reached ours — this is how to read it. An FDA advisory committee just recommended four peptides for compounding, against its ...